Role of PPARgamma in ultraviolet stress responses
PPARγ 在紫外线应激反应中的作用
基本信息
- 批准号:7460816
- 负责人:
- 金额:$ 7.4万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2007
- 资助国家:美国
- 起止时间:2007-07-01 至 2009-06-30
- 项目状态:已结题
- 来源:
- 关键词:AcuteAffectAgonistAnti-psoriatic AgentApoptosisApplications GrantsBiological ModelsCell LineCellular Stress ResponseChemopreventive AgentChronicClassClinicalCutaneousDataDevelopmentDinoprostoneEpidermisFutureGene TargetingGoalsHomeostasisHormonesHumanHyperplasiaIn VitroInbred NOD MiceInflammatoryIonizing radiationLeadLeftLesionLigandsLightLipidsMalignant NeoplasmsMediatingMediator of activation proteinModalityModelingNeoplasmsNon-Insulin-Dependent Diabetes MellitusOxidative StressOxygenPPAR gammaPathologicPathway interactionsPatientsPeroxisome Proliferator-Activated ReceptorsPlayProcessProductionPromoter RegionsProstaglandin ProductionProstaglandin-Endoperoxide SynthasePsoriasisRXRRateRoleSignal TransductionSkinSolar EnergyStreamSystemThinkingUltraviolet RaysXenograft procedurebiological adaptation to stresscell growthciglitazonecopingcyclooxygenase 1cyclooxygenase 2diabeticin vivo Modelkeratinocytekeratinocyte differentiationmemberneoplasticnovelresponseskin disorderultraviolet
项目摘要
DESCRIPTION (provided by applicant):
Ultraviolet B (UVB) exposure is the primary cause of cutaneous neoplasia and also is an effective treatment modality for inflammatory skin lesions like psoriasis. We have recently shown that UVB exposure is a potent activator of the ligand-activated transcriptional regulator, peroxisome proliferator activated receptor-gamma (PPARgamma). Thus, PPARgamma activation may play a key role in regulating UVBmediated cellular stress responses in the epidermis. In line with this idea, we have shown in two different cell lines, including primary keratinocytes (PHKs), that UVB mediated cyclooxygenase 2 (COX-2) induction is PPARgamma dependent. Moreover, we show that ciglitazone, a member of a commonly prescribed class of anti-diabetic PPARgamma agonists, is also capable of inducing COX-2 expression in PHKs. Given that UVB, COX-2, and PPARgamma have all been shown to independently alter cellular growth, differentiation, and apoptosis, we hypothesize that many of these UVB-mediated cellular stress responses may be due to PPARgamma activation, either in a COX-2 dependent or independent fashion. In line with this hypothesis, we provide evidence that PPARgamma alters keratinocyte differentiation and apoptosis. In this grant application, we propose to further define which of these UVB-mediated cellular stress responses are PPARgamma dependent. This will be done using both in vitro and in vivo models to examine how activation of PPARgamma alters cellular growth, differentiation and apoptosis. This will be done both in the context of UVB-mediated PPARgamma activation, as well activation of PPARgamma alone. The role of COX-2 induction in these processes will also be examined. These studies are particularly important given that recent studies indicate that several PPARgamma agonists commonly used to treat type II diabetes may have cancer chemopreventive activity and may also be effective anti-psoriatic agents. This data can then be used to focus future studies on determining whether the PPARgamma system augments or suppresses UVB photocarcinogenesis, as well as determine what role PPARgamma plays in UVB-mediated treatment of inflammatory skin disease. Given the increasing rates of type II diabetes and the need to treat these patients over the long term with PPARgamma agonists, it is particularly important to have a greater understanding of the role these agents play in UVB photocarcinogenesis.
描述(由申请人提供):
紫外线B(UVB)暴露是皮肤肿瘤的主要原因,也是牛皮癣等炎症性皮肤病变的有效治疗方式。我们最近表明,UVB暴露是配体激活的转录调节剂,过氧化物酶体增殖物激活受体伽马(PPARGAMMA)的有效活化剂。因此,ppargamma激活在调节表皮中的UVB介导的细胞应激反应中可能起关键作用。与这个想法一致,我们已经以两种不同的细胞系(包括原代角质形成细胞(PHK))显示了UVB介导的环氧酶2(COX-2)诱导是PPARGAMMA依赖性的。此外,我们表明,Ciglitazone是常见类别的抗糖尿病性ppargamma激动剂的成员,也能够在PHKS中诱导COX-2表达。鉴于UVB,COX-2和PPARGAMMA均已证明可以独立改变细胞的生长,分化和凋亡,因此我们假设许多这些UVB介导的细胞应激反应可能是由于PPARGAMMA激活所致,这是在COX-2-2依赖或独立的时尚。根据这一假设,我们提供了ppargamma改变角质形成细胞分化和凋亡的证据。在此赠款应用中,我们建议进一步定义这些UVB介导的细胞应力反应中的哪些是ppargamma的。这将使用体外和体内模型同时研究,以检查ppargamma的激活如何改变细胞的生长,分化和凋亡。这将在UVB介导的ppargamma激活以及单独激活Ppargamma的情况下进行。还将检查COX-2诱导在这些过程中的作用。这些研究尤其重要,因为最近的研究表明,几种通常用于治疗II型糖尿病的PPARGAMMA激动剂可能具有癌症化学预防活性,并且也可能是有效的抗PSoriatic剂。然后,这些数据可用于将未来的研究集中在确定PPARGAMMA系统是否增加或抑制UVB光碳纤维促促症状,并确定ppargamma在UVB介导的炎症性皮肤病治疗中的作用。鉴于II型糖尿病的发生率不断提高,并且需要长期使用PPARGAMMA激动剂来治疗这些患者,因此对这些药物在UVB光致促促炎中的作用有更深入的了解,这一点尤其重要。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
RAYMOND L KONGER其他文献
RAYMOND L KONGER的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('RAYMOND L KONGER', 18)}}的其他基金
Promotion of photocarcinogenesis by the senescent field and mechanisms for field persistence
衰老场促进光致癌作用和场持久性机制
- 批准号:
10487791 - 财政年份:2022
- 资助金额:
$ 7.4万 - 项目类别:
Regulation of cutaneous immune function and anti-tumor immune responses by PPARgamma-mediated transrepressive signaling
PPARgamma 介导的反式抑制信号调节皮肤免疫功能和抗肿瘤免疫反应
- 批准号:
9898276 - 财政年份:2017
- 资助金额:
$ 7.4万 - 项目类别:
Regulation of cutaneous immune function and anti-tumor immune responses by PPARgamma-mediated transrepressive signaling
PPARγ介导的反式抑制信号调节皮肤免疫功能和抗肿瘤免疫反应
- 批准号:
10450626 - 财政年份:2017
- 资助金额:
$ 7.4万 - 项目类别:
Characterization of persistent hyperemic foci and their role in photocarcinogenes
持续充血病灶的特征及其在光致癌物中的作用
- 批准号:
8385329 - 财政年份:2012
- 资助金额:
$ 7.4万 - 项目类别:
Characterization of persistent hyperemic foci and their role in photocarcinogenes
持续充血病灶的特征及其在光致癌物中的作用
- 批准号:
8529530 - 财政年份:2012
- 资助金额:
$ 7.4万 - 项目类别:
Tumor Suppression Through Oxidized Glycerophosphocholines
通过氧化甘油磷酸胆碱抑制肿瘤
- 批准号:
8073411 - 财政年份:2010
- 资助金额:
$ 7.4万 - 项目类别:
Tumor Suppression Through Oxidized Glycerophosphocholines
通过氧化甘油磷酸胆碱抑制肿瘤
- 批准号:
7894989 - 财政年份:2009
- 资助金额:
$ 7.4万 - 项目类别:
Tumor Suppression Through Oxidized Glycerophosphocholines
通过氧化甘油磷酸胆碱抑制肿瘤
- 批准号:
7708753 - 财政年份:2009
- 资助金额:
$ 7.4万 - 项目类别:
Role of PPARgamma in ultraviolet stress responses
PPARγ 在紫外线应激反应中的作用
- 批准号:
7304147 - 财政年份:2007
- 资助金额:
$ 7.4万 - 项目类别:
ROLE OF PGE2 RECEPTORS EP2 AND EP3 ON SENESCENCE
PGE2 受体 EP2 和 EP3 对衰老的作用
- 批准号:
6196488 - 财政年份:2000
- 资助金额:
$ 7.4万 - 项目类别:
相似国自然基金
β2AR激动剂与微秒电刺激对大鼠肛提肌线粒体有氧代谢酶及其多模态影像表型的影响研究
- 批准号:
- 批准年份:2021
- 资助金额:30 万元
- 项目类别:青年科学基金项目
环境激素壬基酚对变应性鼻炎的影响及其对GPER特异性激动剂G-1在变应性鼻炎治疗作用中的干扰机制研究
- 批准号:82000963
- 批准年份:2020
- 资助金额:24 万元
- 项目类别:青年科学基金项目
促生长激素释放激素激动剂抑制平滑肌细胞转分化对动脉粥样硬化的影响及机制研究
- 批准号:81900389
- 批准年份:2019
- 资助金额:21.0 万元
- 项目类别:青年科学基金项目
五羟色胺2C受体激动剂对2型糖尿病小鼠β细胞功能的影响及机制研究
- 批准号:81803644
- 批准年份:2018
- 资助金额:21.0 万元
- 项目类别:青年科学基金项目
cAMP信号激动剂对恶性胶质瘤血管新生和血管正常化的影响及机制研究
- 批准号:81803568
- 批准年份:2018
- 资助金额:21.0 万元
- 项目类别:青年科学基金项目
相似海外基金
Integrating Tailored Postoperative Opioid Tapering and Pain Management Support for Patients on Long-Term Opioid Use Presenting for Spine Surgery (MIRHIQL)
为脊柱手术中长期使用阿片类药物的患者整合定制的术后阿片类药物逐渐减量和疼痛管理支持 (MIRHIQL)
- 批准号:
10722943 - 财政年份:2023
- 资助金额:
$ 7.4万 - 项目类别:
A Novel Assay to Improve Translation in Analgesic Drug Development
改善镇痛药物开发转化的新方法
- 批准号:
10726834 - 财政年份:2023
- 资助金额:
$ 7.4万 - 项目类别:
Preclinical validation of small molecule immunomodulators for the treatment of Crohn's disease
小分子免疫调节剂治疗克罗恩病的临床前验证
- 批准号:
10600659 - 财政年份:2023
- 资助金额:
$ 7.4万 - 项目类别:
Post-translational Modification of Cx43 Regulates Myometrial Quiescence
Cx43 的翻译后修饰调节子宫肌层静止
- 批准号:
10575364 - 财政年份:2023
- 资助金额:
$ 7.4万 - 项目类别:
Alcohol-induced epigenetic reprogramming of PPAR-α affects allopregnanolone biosynthesis
酒精诱导的 PPAR-α 表观遗传重编程影响异孕酮生物合成
- 批准号:
10658534 - 财政年份:2023
- 资助金额:
$ 7.4万 - 项目类别: